Introduction and Historical Landmarks • Definition of the Photodynamic Action • Optimum Photosensitizing Agent for Photodynamic Action • Definition of Fluorescence Detection with ALA- Induced Porphyrins (FDAP) • Mechanisms of Action in PDT d-Aminolevulinic Acid (ALA) • Chemistry of ALA and ALA Methylester (ALA) • Metabolism of ALA • Pharmacodynamics of ALA Light Used in FDAP and PDT Unresolved Issues ind FDAP and PDT Fluorescence Detection of ALA-induced Porphyrins (FDAP) • FDAP: Evaluation of the ALA-Induced Fluoresence in Skin Diseases Ex vivo – Investigations on ALA-induced Porphyrins • Porphyrin Accumulation in Cells (in vitro) • Porphyrin Accumulation in Skin Tumors, Colon and Bronchial Carcinomas after Administration of ALA (ex vivo) In vivo – Investigations on ALA-Induced Porphyrin/FDAP • FDAP: Kinetics of ALA-induced Porphyrins in Human Cutaneous Tumors, Psoriasis Lesions and Normal Skin • FDAP: Kinetics of PorphyrinAccumulation in Solar Keratoses: ALA versus ALA Methylester • FDAP: use of the in vivo – Fluorescence for Surgical Planning • FDAP: Evaluation of the Optimum Photosensitizing Substance or its Prodrug • FDAP: Evaluation of the Optimum Exciting Light Source • FDAP: Correlation of in vivo – Tumor Fluorescence and Histopathology • FDAP: Course of FDAP in Relation to the Number of PDT-Sessions The Clinical Use of FDAP • FDAP in Clinically Well-defined Tumors • FDAP in Clinically Ill-defined Lesions • FDAP in Pretreated or Damaged Skin • Limitations of FDAP • Usefulness of FDAP in Guiding Tumor Therapies Photodynamic Therapy in Cutaneous Diseases • PDT: Evaluation of the Efficacy in Solar Keratoses • PDT: Evaluation of the Efficacy in Bowen`s Disease • PDT: Evaluation of the Efficacy in Basal Cell Carcinoma • PDT: Evaluation of the Efficacy Sqamous Cell Carcinoma • PDT: Evaluation of the Efficacy in Psoriatric Lesions • PDT: Evaluation ofthe Efficacy in Selected Cutaneous Diseases • PDT in Skin Cancers and Precanceroses Others than Discussed Above • PDT in Tumors of the Oral Mucosa • PDT in Non-neoplastic Skin Diseases • PDT in Non-dermatological Indications • PDT: Evaluation of the Optimum Photosensitizing Substance or its Prodrug • PDT: Evaluation of the Optimum Exciting Light Source General Discussion • FDAP: Indications and Limits • PDT: Indications and Limits • Safety and Tolerability of ALA-PDT • Regulatory Affairs Concerning Aminolevulinic Acid • Regulatory Affairs Concerning Aminolevulinic Acid Methylester Conclusion Summary
